BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33891299)

  • 1. Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.
    Strojnik K; Krajc M; Dragos VS; Stegel V; Novakovic S; Blatnik A
    Breast Cancer Res Treat; 2021 Aug; 188(3):811-820. PubMed ID: 33891299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA2 gene mutations in Slovenian male breast cancer patients.
    Besic N; Cernivc B; de Grève J; Lokar K; Krajc M; Novakovic S; Zgajnar J; Teugels E
    Genet Test; 2008 Jun; 12(2):203-9. PubMed ID: 18439106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
    Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
    BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.
    Miolo G; Puppa LD; Santarosa M; De Giacomi C; Veronesi A; Bidoli E; Tibiletti MG; Viel A; Dolcetti R
    BMC Cancer; 2006 Jun; 6():156. PubMed ID: 16764716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.
    Stegel V; Krajc M; Zgajnar J; Teugels E; De Grève J; Hočevar M; Novaković S
    BMC Med Genet; 2011 Jan; 12():9. PubMed ID: 21232165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.
    Krajc M; Teugels E; Zgajnar J; Goelen G; Besic N; Novakovic S; Hocevar M; De Grève J
    BMC Med Genet; 2008 Sep; 9():83. PubMed ID: 18783588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA2 founder mutation in Slovenian breast cancer families.
    Krajc M; De Grève J; Goelen G; Teugels E
    Eur J Hum Genet; 2002 Dec; 10(12):879-82. PubMed ID: 12461697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
    Deb S; Jene N; ; Fox SB
    BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.
    Kwon WK; Jang HJ; Lee JE; Park YH; Ryu JM; Yu J; Jang JH; Kim JW
    Cancer Genet; 2022 Aug; 266-267():19-27. PubMed ID: 35671604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Fostira F; Saloustros E; Apostolou P; Vagena A; Kalfakakou D; Mauri D; Tryfonopoulos D; Georgoulias V; Yannoukakos D; Fountzilas G; Konstantopoulou I
    Breast Cancer Res Treat; 2018 May; 169(1):105-113. PubMed ID: 29335925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five Italian Families with Two Mutations in
    Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Dello Ioio C; Cioffi M; Molinari AM
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33287145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
    Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
    Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
    Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.